Literature DB >> 31219513

Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment.

Mark J Ratain1,2, Daniel A Goldstein3, Allen S Lichter2.   

Abstract

Year:  2019        PMID： 31219513     DOI： 10.1001/jamaoncol.2019.1341

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  8 in total

Review 1.  Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will.

Authors:  Ajay Major; Blase N Polite
Journal:  Cancer J       Date:  2020 Jul/Aug       Impact factor: 2.074

2.  Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions.

Authors:  Aakash Desai; Bishal Gyawali
Journal:  EClinicalMedicine       Date:  2020-01-31

3.  Clinical research in oncology: in memory of Professor Gordon McVie.

Authors:  Ian F Tannock
Journal:  Ecancermedicalscience       Date:  2022-01-13

4.  Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.

Authors:  Po-Hung Hsieh; Alec J Kacew; Marie Dreyer; Anthony V Serritella; Randall W Knoebel; Garth W Strohbehn; Mark J Ratain
Journal:  NPJ Breast Cancer       Date:  2022-03-14

Review 5.  Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course.

Authors:  Mengjie Jiang; Yujie Hu; Gang Lin; Chao Chen
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

6.  Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors.

Authors:  Maddalena Centanni; Lena E Friberg
Journal:  Front Pharmacol       Date:  2020-03-12       Impact factor: 5.810

7.  Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.

Authors:  Garth W Strohbehn; Pankti D Reid; Mark J Ratain
Journal:  Clin Pharmacol Ther       Date:  2020-07-04       Impact factor: 6.903

8.  COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.

Authors:  Garth W Strohbehn; Brian L Heiss; Sherin J Rouhani; Jonathan A Trujillo; Jovian Yu; Alec J Kacew; Emily F Higgs; Jeffrey C Bloodworth; Alexandra Cabanov; Rachel C Wright; Adriana K Koziol; Alexandra Weiss; Keith Danahey; Theodore G Karrison; Cuoghi C Edens; Iazsmin Bauer Ventura; Natasha N Pettit; Bhakti K Patel; Jennifer Pisano; Mary E Strek; Thomas F Gajewski; Mark J Ratain; Pankti D Reid
Journal:  Clin Pharmacol Ther       Date:  2020-12-10       Impact factor: 6.903
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.